Passa al contenuto
Merck
Tutte le immagini(2)

Key Documents

HCMBMAG-22K

Millipore

MILLIPLEX® Human Cancer/ Metastasis Biomarker Magnetic Bead Panel - Cancer Multiplex Assay

Circulating Cancer and Metastasis Biomarker Bead-Based Multiplex Assays using the Luminex technology enables the simultaneous analysis of multiple oncology biomarkers in various tumor types in human serum, plasma and cell culture samples.

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Livello qualitativo

Reattività contro le specie

human

Produttore/marchio commerciale

Milliplex®

assay range

accuracy: 70-105%
standard curve range: 0,019-80 ng/mL
(TRAP5)

standard curve range: 0,048-20 ng/mL
(YKL40)

standard curve range: 0.002-10 ng/mL
(GDF15)

standard curve range: 0.007-30 ng/mL
(DKK-1)

standard curve range: 0.007-30 ng/mL
(OPG)

standard curve range: 0.036-150 ng/mL
(NSE)

standard curve range: 0.195-800 ng/mL
(Periostin)

standard curve range: 0.976-4,00 0 ng/mL
(Osteonectin (SPARC))

inter-assay cv: <16%
intra-assay cv: <10%

tecniche

multiplexing: suitable

Metodo di rivelazione

fluorometric (Luminex xMAP)

Condizioni di spedizione

wet ice

Descrizione generale

The MILLIPLEX®Human Cancer/Metastasis Biomarker Panel 1 contains nine metastasis biomarkers that have also been identified in a variety of tumor types. Coupled with the Luminex® xMAP® platform in bead format, this panel enables researchers to focus on discovery with the advantage of simultaneous quantitative multiplex detection leading to speed and sensitivity.

Metastasis is a complex process in which tumor cells leave the primary tumor site and migrate to other parts of the body via blood and lymph vessels or by tumor invasion of surrounding tissues and organs. Breaking away from the primary tumor, cancer cells attach to and degrade extracellular matrix proteins that separate tumor from surrounding tissues to escape into the stroma. Where metastases form often depends on the primary tumor. Bone metastases, for example, tend to arise from breast, prostate and kidney tumors. This organ/tissue specificity seems to involve chemical signals from both chemokines and growth factors.

Panel Type: Circulating Cancer

Applicazioni

  • Analytes: DKK-1, GDF-15, Neuron-specific Enolase (NSE), Osteonectin (SPARC), Osteoprotegerin (OPG), Periostin, TRAP5, TWEAK, YKL40 (CHI3L1)
  • Recommended Sample Type: Human serum, plasma, and tissue/cell culture supernatants or lysates
  • Recommended Sample Dilution: 25 μL of 1:10 diluted serum or plasma; tissue/cell culture supernatants or lysates diluted may be diluted as needed in appropriate control medium
  • Assay Run Time: Overnight (16-18 hours) at 2-8°C
  • Research Category: Cancer

Caratteristiche e vantaggi

Design your multiplex kit by choosing available analytes within this panel.

Altre note

Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.

Note legali

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Avvertenze

Danger

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Organi bersaglio

Respiratory Tract

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Paul G Corn et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(5), 990-999 (2020-01-17)
Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (ADT) in hormone-naïve metastatic prostate cancer (HNMPCa). Patients received ADT plus cabozantinib

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.